Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Tuberculosis

Free Subscription Articles published in Emerg Infect Dis Retrieve available abstracts of 31 articles: HTML format

Single Articles

March 2025
1. PAUL R, Lorenzo F, Lopez B, Alegre MG, et al
   Outbreak Caused by Multidrug-Resistant Mycobacterium Tuberculosis with Unusual Combination of Resistance Mutations, Northern Argentina, 2006-2022.
   Emerg Infect Dis. 2025;31:601-606.
   PubMed     Abstract available
   
   
   
2. KLINKENBERG E, de Haas P, Manyonge C, Namutebi J, et al
   Lessons Learned from Early Implementation and Scale-up of Stool-Based Xpert Testing to Diagnose Tuberculosis in Children.
   Emerg Infect Dis. 2025;31:1-9.
   PubMed     Abstract available
   
   
   
3. GERUSSI V, Petersen T, Bonnet I, Aubry A, et al
   Evaluation of High-Dose Isoniazid in Multidrug-Resistant Tuberculosis Treatment.
   Emerg Infect Dis. 2025;31:633-636.
   PubMed     Abstract available
   
   
   
4. FRANCISCO NM, Gaviraghi A, Alladio F, Huits R, et al
   Multidrug-Resistant Mycobacterium tuberculosis in a Community Hospital, Luanda, Angola.
   Emerg Infect Dis. 2025;31:627-629.
   PubMed     Abstract available
   
   
   
5. KONSTANTYNOVSKA O, Synenko T, Honcharenko A, Volobuieva O, et al
   Fluoroquinolone Resistance in Drug-Resistant Tuberculosis, Kharkiv, Ukraine, 2019-2023.
   Emerg Infect Dis. 2025;31:615-617.
   PubMed     Abstract available
   
   
   
6. JUNG E, Alarcon VA, Solis Tupes WS, Avalos-Cruz T, et al
   National Active Case-Finding Program for Tuberculosis in Prisons, Peru, 2024.
   Emerg Infect Dis. 2025;31:564-568.
   PubMed     Abstract available
   
   
   
7. SHRESTHA S, Cilloni L, Asay GRB, Kammerer JS, et al
   Model-Based Analysis of Impact, Costs, and Cost-effectiveness of Tuberculosis Outbreak Investigations, United States.
   Emerg Infect Dis. 2025;31:497-506.
   PubMed     Abstract available
   
   
   
8. ZIMENKOV D, Ushtanit A, Gordeeva E, Guselnikova E, et al
   High Prevalence of atpE Mutations in Bedaquiline-Resistant Mycobacterium tuberculosis Isolates, Russia.
   Emerg Infect Dis. 2025;31:525-536.
   PubMed     Abstract available
   
   
   
9. KURBATOVA EV, Whitworth WC, Peddareddy LP, Phillips PPJ, et al
   Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes.
   Emerg Infect Dis. 2025;31:467-476.
   PubMed     Abstract available
   
   
   November 2024
10. GORVETZIAN S, Pacheco AG, Anderson E, Ray SM, et al
    Mortality Rates after Tuberculosis Treatment, Georgia, USA, 2008-2019.
    Emerg Infect Dis. 2024;30:2261-2270.
    PubMed     Abstract available
    
    
    August 2024
11. MCQUAID CF, Ryckman TS, Menzies NA, White RG, et al
    Potential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance.
    Emerg Infect Dis. 2024;30:1571-1579.
    PubMed     Abstract available
    
    
    July 2024
12. LUKOYE D, Kalamya JN, Awor AC, Gustavson G, et al
    Treatment Outcomes for Tuberculosis Infection and Disease Among Persons Deprived of Liberty, Uganda, 2020.
    Emerg Infect Dis. 2024;30:1402-1405.
    PubMed     Abstract available
    
    
    June 2024
13. TAN Q, Huang CC, Becerra MC, Calderon R, et al
    Chest Radiograph Screening for Detecting Subclinical Tuberculosis in Asymptomatic Household Contacts, Peru.
    Emerg Infect Dis. 2024;30:1115-1124.
    PubMed     Abstract available
    
    
    April 2024
14. FUKUNAGA R, Pierre P, Williams JK, Briceno-Robaugh R, et al
    Prioritizing Mental Health within HIV and Tuberculosis Services in PEPFAR.
    Emerg Infect Dis. 2024;30:1-5.
    PubMed     Abstract available
    
    
    
15. DAHL VN, Butova T, Rosenthal A, Grinev A, et al
    Drug-Resistant Tuberculosis, Georgia, Kazakhstan, Kyrgyzstan, Moldova, and Ukraine, 2017-2022.
    Emerg Infect Dis. 2024;30:831-833.
    PubMed     Abstract available
    
    
    
16. GURREY SO, Strick LB, Dov LK, Miller JS, et al
    Lessons Learned from Public Health and State Prison Collaborations during COVID-19 Pandemic and Multifacility Tuberculosis Outbreak, Washington, USA.
    Emerg Infect Dis. 2024;30:S17-S20.
    PubMed     Abstract available
    
    
    March 2024
17. SPIES R, Hong HN, Trieu PP, Lan LK, et al
    Spatial Analysis of Drug-Susceptible and Multidrug-Resistant Cases of Tuberculosis, Ho Chi Minh City, Vietnam, 2020-2023.
    Emerg Infect Dis. 2024;30:499-509.
    PubMed     Abstract available
    
    
    
18. GUNTHER G, Mhuulu L, Diergaardt A, Dreyer V, et al
    Bedaquiline Resistance after Effective Treatment of Multidrug-Resistant Tuberculosis, Namibia.
    Emerg Infect Dis. 2024;30:568-571.
    PubMed     Abstract available
    
    
    January 2024
19. HAN E, Nabity SA, Dasgupta-Tsinikas S, Guevara RE, et al
    Tuberculosis Diagnostic Delays and Treatment Outcomes among Patients with COVID-19, California, USA, 2020.
    Emerg Infect Dis. 2024;30:136-140.
    PubMed     Abstract available
    
    
    
20. HUMAYUN M, Mukasa L, Ye W, Bates JH, et al
    Racial and Ethnic Disparities in Tuberculosis Incidence, Arkansas, USA, 2010-2021.
    Emerg Infect Dis. 2024;30:116-124.
    PubMed     Abstract available
    
    
    
21. NSENGIYUMVA NP, Khan A, Gler MMTS, Tonquin ML, et al
    Costs of Digital Adherence Technologies for Tuberculosis Treatment Support, 2018-2021.
    Emerg Infect Dis. 2024;30:79-88.
    PubMed     Abstract available
    
    
    December 2023
22. LAFLEUR M, Rasoanaivo HA, Andrianarivo TH, Andrianomanana FR, et al
    Tuberculosis in Lemurs and a Fossa at National Zoo, Madagascar, 2022.
    Emerg Infect Dis. 2023;29:2587-2589.
    PubMed     Abstract available
    
    
    November 2023
23. MODONGO C, Barilar I, Wang Q, Molefi T, et al
    Tuberculosis Variant with Rifampin Resistance Undetectable by Xpert MTB/RIF, Botswana.
    Emerg Infect Dis. 2023;29:2403-2406.
    PubMed     Abstract available
    
    
    October 2023
24. WINSTON CA, Marks SM, Carr W
    Estimated Costs of 4-Month Pulmonary Tuberculosis Treatment Regimen, United States.
    Emerg Infect Dis. 2023;29:2102-2104.
    PubMed     Abstract available
    
    
    August 2023
25. NABITY SA, Marks SM, Goswami ND, Smith SR, et al
    Characteristics of and Deaths among 333 Persons with Tuberculosis and COVID-19 in Cross-Sectional Sample from 25 Jurisdictions, United States.
    Emerg Infect Dis. 2023;29.
    PubMed     Abstract available
    
    
    
26. LOUIE JK, Agraz-Lara R, Romo L, Deiterich C, et al
    Uniting for Ukraine Tuberculosis Screening Experience, San Francisco, California, USA.
    Emerg Infect Dis. 2023;29:1651-1654.
    PubMed     Abstract available
    
    
    July 2023
27. WOODRUFF R, Miramontes R
    Tuberculosis Infection among Non-US-Born Persons and Persons >/=60 Years of Age, United States, 2019-2020.
    Emerg Infect Dis. 2023;29:1470-1472.
    PubMed     Abstract available
    
    
    May 2023
28. NOROC E, Chesov D, Merker M, Groschel MI, et al
    Limited Nosocomial Transmission of Drug-Resistant Tuberculosis, Moldova.
    Emerg Infect Dis. 2023;29:1046-1050.
    PubMed     Abstract available
    
    
    
29. NGUYEN HV, Brals D, Tiemersma E, Gasior R, et al
    Influence of Sex and Sex-Based Disparities on Prevalent Tuberculosis, Vietnam, 2017-2018.
    Emerg Infect Dis. 2023;29:967-976.
    PubMed     Abstract available
    
    
    
30. BAKER CR, Barilar I, de Araujo LS, Rimoin AW, et al
    Use of High-Resolution Geospatial and Genomic Data to Characterize Recent Tuberculosis Transmission, Botswana.
    Emerg Infect Dis. 2023;29:977-987.
    PubMed     Abstract available
    
    
    
31. MILLARD J, Rimmer S, Nimmo C, O'Donnell M, et al
    Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB.
    Emerg Infect Dis. 2023;29:1081-1084.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge.